<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite advances in diagnosis and therapy, <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> remains a highly lethal disease </plain></SENT>
<SENT sid="1" pm="."><plain>The incidence of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (EAC) has risen faster than that of any other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in the western world, and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) may be a significant contributing factor </plain></SENT>
<SENT sid="2" pm="."><plain>In-depth knowledge of biology of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">cancer progression</z:e> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> could lead to the identification of biomarkers that are the hallmark of BE's progression </plain></SENT>
<SENT sid="3" pm="."><plain>By integrating validated biomarkers of progression into clinical practice, there is a possibility of identifying high-risk patient population for targeted surveillance, and such biomarkers may serve as novel therapeutic targets for chemoprevention and therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical management of BE has improved considerably due to the improvements in endoscopic resection and ablation techniques </plain></SENT>
<SENT sid="5" pm="."><plain>We discuss the current status of biology and therapeutic approaches to BE </plain></SENT>
</text></document>